EVO

Business Context and Reporting Period

Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter ended June 30, 2009 (First Half 2009 data also provided)
Business Overview: Evotec is a leader in the discovery and development of novel small molecule drugs, operating through Discovery Alliances Business (DAB) and proprietary clinical programs. The company is executing a restructuring program titled "Evotec 2012 - Action Plan to Focus and Grow."

Key Financial Metrics

Note: Liquidity includes EUR 38.4 million cash, EUR 25.2 million short-term investments, and EUR 9.1 million auction rate securities.

Material Changes vs. Prior Period

• Revenue Growth: Q2 revenue increased 46% year-over-year, driven by strong Discovery Alliances performance, a EUR 0.9 million upfront payment from Roche (EVT 100 family), and EUR 1.8 million in license/royalty income from Roche and DeveloGen.
• Operating Performance: Operating loss improved by 29% in Q2 despite EUR 2.7 million in restructuring expenses. This was achieved through a 35% reduction in R&D expenses and an 11% reduction in SG&A expenses.
• One-Time Items: H1 2009 results included a EUR 6.6 million impairment charge related to the VR1 program (Pfizer collaboration) and EUR 4.1 million in restructuring expenses. Excluding these, the adjusted operating loss for H1 improved by 31%.
• Cost Structure: Headcount decreased by 60 employees (14%) compared to the prior year due to the "Evotec 2012" plan, including a 50% reduction in the clinical development group and 20% in administrative functions.

Guidance, Outlook, and Risks

Guidance and Outlook

• Revenue: 2009 revenue guidance increased to above EUR 40 million (previously above EUR 35 million).
• Liquidity: Management expects year-end 2009 liquidity to exceed EUR 65 million, citing reduced cash consumption from restructuring and milestone receipts.
• Expenses: R&D spending is expected to be below EUR 30 million for 2009. SG&A expenses are projected to decline further.

Management Commentary and Unusual Items

• Acquisitions: Post-period-end, Evotec acquired a controlling stake in Indian firm RSIPL for approx. EUR 2.8 million to expand chemistry capacity. Also acquired zebrafish screening operations from Summit Corporation in May 2009.
• Clinical Pipeline:
  • Failure: EVT 302 (smoking cessation) failed Phase II endpoints; development stopped.
  • Success: EVT 401 (inflammatory conditions) completed successful Phase I; Phase II preparations underway.
  • Partnerships: Roche alliance for EVT 100 family (potential payments >$300 million); new collaborations with Cubist Pharmaceuticals and Alios Biopharma.

Risks and Contingencies

• Clinical Risk: Failure of product candidates in clinical trials (e.g., EVT 302) reduces portfolio value and partnering opportunities.
• Liquidity Risk: Uncertainty regarding the ability to reduce cash burn sufficiently through restructuring measures.
• Market Risk: Valuation of auction rate securities (ARS) involves liquidity risk; currently valued at a ~10% discount to par.
• Regulatory Risk: Dependence on FDA and international regulatory approvals for drug candidates.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of Q2 revenue growth, which was significantly boosted by one-time upfront payments (Roche) and royalty income (DeveloGen).
• Restructuring Execution: Confirm the timeline and cost savings associated with the closure of US operations in South San Francisco and the integration of RSIPL.
• Clinical Pipeline Viability: Assess the impact of the EVT 302 failure on the proprietary portfolio and the progress of EVT 401 and EVT 101.
• Liquidity Position: Monitor the valuation and liquidity of auction rate securities (ARS) and the actual cash burn rate in H2 2009 against the EUR 65 million year-end target.
• Non-GAAP Adjustments: Review the reconciliation between reported IFRS results and adjusted operating loss, specifically regarding the exclusion of impairment and restructuring costs.